Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.

<h4>Background</h4>A non-inferiority (NI) trial is intended to show that the effect of a new treatment is not worse than the comparator. We conducted a review to identify how NI trials were conducted and reported, and whether the standard requirements from the guidelines were followed.&l...

Full description

Saved in:
Bibliographic Details
Main Authors: Grace Wangge, Olaf H Klungel, Kit C B Roes, Anthonius de Boer, Arno W Hoes, Mirjam J Knol
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-10-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0013550&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849419174257885184
author Grace Wangge
Olaf H Klungel
Kit C B Roes
Anthonius de Boer
Arno W Hoes
Mirjam J Knol
author_facet Grace Wangge
Olaf H Klungel
Kit C B Roes
Anthonius de Boer
Arno W Hoes
Mirjam J Knol
author_sort Grace Wangge
collection DOAJ
description <h4>Background</h4>A non-inferiority (NI) trial is intended to show that the effect of a new treatment is not worse than the comparator. We conducted a review to identify how NI trials were conducted and reported, and whether the standard requirements from the guidelines were followed.<h4>Methodology and principal findings</h4>From 300 randomly selected articles on NI trials registered in PubMed at 5 February 2009, we included 227 NI articles that referred to 232 trials. We excluded studies on bioequivalence, trials on healthy volunteers, non-drug trials, and articles of which the full-text version could not be retrieved. A large proportion of trials (34.0%) did not use blinding. The NI margin was reported in 97.8% of the trials, but only 45.7% of the trials reported the method to determine the margin. Most of the trials used either intention to treat (ITT) (34.9%) or per-protocol (PP) analysis (19.4%), while 41.8% of the trials used both methods. Less than 10% of the trials included a placebo arm to confirm the efficacy of the new drug and active comparator against placebo, and less than 5.0% were reporting the similarity of the current trial with the previous comparator's trials. In general, no difference was seen in the quality of reporting before and after the release of the CONSORT statement extension 2006 or between the high-impact and low-impact journals.<h4>Conclusion</h4>The conduct and reporting of NI trials can be improved, particularly in terms of maximizing the use of blinding, the use of both ITT and PP analysis, reporting the similarity with the previous comparator's trials to guarantee a valid constancy assumption, and most importantly reporting the method to determine the NI margin.
format Article
id doaj-art-869e1b8d444f4c609264e085fa2ee0be
institution Kabale University
issn 1932-6203
language English
publishDate 2010-10-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-869e1b8d444f4c609264e085fa2ee0be2025-08-20T03:32:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-10-01510e1355010.1371/journal.pone.0013550Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.Grace WanggeOlaf H KlungelKit C B RoesAnthonius de BoerArno W HoesMirjam J Knol<h4>Background</h4>A non-inferiority (NI) trial is intended to show that the effect of a new treatment is not worse than the comparator. We conducted a review to identify how NI trials were conducted and reported, and whether the standard requirements from the guidelines were followed.<h4>Methodology and principal findings</h4>From 300 randomly selected articles on NI trials registered in PubMed at 5 February 2009, we included 227 NI articles that referred to 232 trials. We excluded studies on bioequivalence, trials on healthy volunteers, non-drug trials, and articles of which the full-text version could not be retrieved. A large proportion of trials (34.0%) did not use blinding. The NI margin was reported in 97.8% of the trials, but only 45.7% of the trials reported the method to determine the margin. Most of the trials used either intention to treat (ITT) (34.9%) or per-protocol (PP) analysis (19.4%), while 41.8% of the trials used both methods. Less than 10% of the trials included a placebo arm to confirm the efficacy of the new drug and active comparator against placebo, and less than 5.0% were reporting the similarity of the current trial with the previous comparator's trials. In general, no difference was seen in the quality of reporting before and after the release of the CONSORT statement extension 2006 or between the high-impact and low-impact journals.<h4>Conclusion</h4>The conduct and reporting of NI trials can be improved, particularly in terms of maximizing the use of blinding, the use of both ITT and PP analysis, reporting the similarity with the previous comparator's trials to guarantee a valid constancy assumption, and most importantly reporting the method to determine the NI margin.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0013550&type=printable
spellingShingle Grace Wangge
Olaf H Klungel
Kit C B Roes
Anthonius de Boer
Arno W Hoes
Mirjam J Knol
Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
PLoS ONE
title Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
title_full Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
title_fullStr Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
title_full_unstemmed Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
title_short Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
title_sort room for improvement in conducting and reporting non inferiority randomized controlled trials on drugs a systematic review
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0013550&type=printable
work_keys_str_mv AT gracewangge roomforimprovementinconductingandreportingnoninferiorityrandomizedcontrolledtrialsondrugsasystematicreview
AT olafhklungel roomforimprovementinconductingandreportingnoninferiorityrandomizedcontrolledtrialsondrugsasystematicreview
AT kitcbroes roomforimprovementinconductingandreportingnoninferiorityrandomizedcontrolledtrialsondrugsasystematicreview
AT anthoniusdeboer roomforimprovementinconductingandreportingnoninferiorityrandomizedcontrolledtrialsondrugsasystematicreview
AT arnowhoes roomforimprovementinconductingandreportingnoninferiorityrandomizedcontrolledtrialsondrugsasystematicreview
AT mirjamjknol roomforimprovementinconductingandreportingnoninferiorityrandomizedcontrolledtrialsondrugsasystematicreview